Siamab Therapeutics

90 Bridge Street
Suite 100
Newton
Massachussetts
02458
United States

Tel: 617-714-9773
Fax: 617-752-3653

Email: info@siamab.com

Show jobs for this employer

About Siamab Therapeutics

Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates/glycans. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and overcome chemo-resistance.
YEAR FOUNDED:
2006
LEADERSHIP:
CEO: Jeff Behrens

12 articles with Siamab Therapeutics